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Abstract
The administration of recombinant Factor VIII (FVIII) is the first line therapy for Hemophilia A
(HA), but 25–35% of patients develop an inhibitory antibody response. In general, the presence of
aggregates contributes to unwanted immunogenic responses against therapeutic proteins. FVIII
has been shown to form both native-like and non-native aggregates. Previously, we showed that
non-native aggregates of FVIII are less immunogenic compared to the native protein. Here we
investigated the effect of native-like aggregates of FVIII on immunogenicity in HA and von
Willebrand Factor knockout (vWF−/−) mice. Mice immunized with native-like aggregates showed
significantly higher inhibitory antibody titers compared to animals that received native FVIII.
Following re-stimulation in vitro with native FVIII, the activation of CD4+ T cells isolated from
mice immunized with native-like aggregates is ~4 fold higher than mice immunized with the
native protein. Furthermore, this is associated with increases in the secretion of pro-inflammatory
cytokines IL-6 and IL-17 in the native-like aggregate treatment group. The results indicate that the
native-like aggregates of FVIII are more immunogenic than native FVIII for both the B cell and T
cell responses.
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INTRODUCTION
Factor VIII is a critical protein in the blood coagulation cascade and its deficiency causes
Hemophilia A, a bleeding disorder1. Administration of recombinant FVIII as a replacement
is the first line of therapy2,3. Clinical complications arise from the development of inhibitory
antibodies against FVIII in 25–35% of severe hemophilia A patients, increasing the
frequency of life threatening bleeding episodes4–6.
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Aggregation and its impact on immunogenicity have been well studied7–9. It is recognized
that the presence of protein aggregates can increase immunogenicity, although little is
known about the relative contribution of various types of aggregates10. There are two types
of non-covalent aggregates that are commonly observed. Non-native aggregates are those in
which the monomeric unit of the protein is partially unfolded11. Conversely, native-like
aggregates are made up of self-assembled monomeric units that retain several
conformational characteristics of native protein12. Recent studies have demonstrated that
non-native aggregates may induce potent antibody responses, but these are not expected to
include a large population of inhibitory antibodies because the native structure of the protein
is lost upon aggregation10,13. In contrast, native-like aggregates have also been shown to be
highly immunogenic and capable of producing inhibitory antibodies14,15. Inhibitory
antibodies frequently target regions of macromolecular interactions that are sensitive to
conformational changes. Hermeling and coworkers demonstrated that antibodies against
recombinant human interferon alpha in transgenic mice induced a breaking of central
tolerance, and that the magnitude of the inhibitory response was directly correlated with an
increase in the percentage of native-like aggregates15.
The aggregation of FVIII is well studied and has been shown to form both native-like and
non-native aggregates16–18. Thermal stress of FVIII at elevated temperatures led to the
formation of non-native aggregates that were stabilized by intermolecular beta-strands16,19.
Previously we showed that these non-native aggregates were less immunogenic than native
FVIII, but acted as a unique antigen18. Extensive characterization of the stability of FVIII
demonstrated that a small conformational fluctuation of the native state is sufficient to form
aggregates16–20. Grillo et al. have shown that incubation of FVIII at 37 °C leads to the
formation of soluble aggregates, initiated by a small transition in the tertiary structure16.
Far-UV circular dichroism (CD) and fluorescence analysis of the species formed at 37 °C
did not show significant conformational changes compared to the native state. The role of
these native-like aggregates of FVIII in eliciting immune responses is not known. Here, we
investigate the effect of native-like aggregates of FVIII on immunogenicity in two
preclinical animal models: Hemophilia A (HA) and von Willebrand Factor deficient
(vWF−/−) mice. We found that the native-like FVIII aggregates are significantly more
immunogenic than the non-aggregated monomeric form of FVIII. The enhanced
immunogenicity of the FVIII aggregates was manifested by an increase in T cell activation,
anti-FVIII antibody production, and the secretion of pro-inflammatory cytokines. Thus the
presence of native-like aggregates will likely have a negative effect upon the therapeutic
efficacy and safety of FVIII in the treatment of HA patients.
MATERIALS AND METHODS
MATERIALS
Full length recombinant FVIII was obtained from Baxter Health Care Corporation
(Carlsbad, CA). IgG-free bovine serum albumin (BSA) and diethanolamine were purchased
from Sigma (St. Louis, MO). Normal coagulation control plasma and FVIII-deficient plasma
were purchased from Trinity Biotech (County Wicklow, Ireland). The monoclonal antibody
ESH8 and aPTT reagents were purchased from American Diagnostica Inc. (Greenwich, CT,
USA). The Coamatic FVIII kit from DiaPharma Group (West Chester, OH) was used to
determine FVIII activity in plasma samples. The Dynal CD4+ negative isolation kit,
RPMI-1640 culture medium, penicillin, streptomycin, L-glutamine, 2-mercaptoethanol, and
polymyxin-B were all obtained from Invitrogen Inc., (Carlsbad, CA). Recombinant murine
Granulocyte Macrophage Colony-Stimulating Factor (rmGMCSF) was obtained from
Peprotech (Rocky Hill, NJ) and heat-inactivated Fetal Bovine Serum was purchased from
Lonza (Basel, Switzerland). 3H-thymidine was obtained from Perkin Elmer, Inc. (Boston,
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MA). All buffer salts and solvents were purchased from Fisher Scientific, (Fair Lawn, NJ).
Cytokines (IL-6, IL-17) were obtained from R&D Systems Inc. (Minneapolis, MN).
Preparation of Aggregates
Native-like aggregates of FVIII were prepared by the method of Grillo and co-workers16.
Briefly, native FVIII in Tris buffer (25 mM Tris, 5 mM CaCl2 and 300 mM NaCl, pH 7.0)
was incubated at 37°C for 6 and 24 hr to form native-like aggregates and are referred as N6
Agg-FVIII and N24 Agg-FVIII, respectively. Non-native aggregates of FVIII were prepared
by incubating FVIII in Tris buffer at 80 °C for 2 min to yield 100% Agg-FVIII 18. This
degraded FVIII was then mixed with native FVIII in a 1:20 or 1:5 ratio to form 5% (5%
Agg-FVIII) and 20% (20% Agg-FVIII) aggregated formulations. Native FVIII, N6 Agg-
FVIII, N24 Agg-FVIII, 5% Agg-FVIII, and 20% Agg-FVIII were then used for
immunogenicity studies in HA and vWF−/− mice. For all samples sterile pyrogen free buffer
was used. All samples were handled under aseptic condition.
Endotoxin Test
All FVIII formulations were tested for the presence of endotoxin using the Endosafe
Endochrome-K® kit (Charles River, MA) to confirm they were below the detection limit of
0.05 EU/mL.
Characterization of Aggregates
The conformational changes associated with aggregation were analyzed by far-UV circular
dichroism (CD) and intrinsic fluorescence spectroscopy as previously described18,19. Far-
UV CD spectra were obtained from 206–240 nm using a J-815 CD spectrophotometer
(Jasco, Easton, MD). Fluorescent emission was measured from 300–400 nm following
excitation at 265 nm on a PTI Quantamaster fluorescence spectrophotometer (Photon
Technology International, Birmingham, NJ). Native FVIII, N6 Agg-FVIII, N24 Agg-FVIII,
and 100% Agg-FVIII were analyzed. The presence of aggregates was also confirmed with
size exclusion chromatography (SEC) on an Aglient 1100 series HPLC (Agilent
Technologies, Santa Clara, CA)21. Briefly, 25 µl of FVIII preparations (40 µg/mL) were
injected into a Biosep-SEC-S-4000 4.6×300mm column (Phenomenex, Torrance, CA)
maintained at 20 °C. Isocratic elution was run at 0.5 mL/min with Tris buffer and monitored
with an Agilent G1321A fluorescent detector set at 285 nm emission/335 nm excitation and
an Agilent G1315B diode array detector set at 215 nm. Percentage of aggregate composition
was determined by comparing the area of the aggregate peak to the total area of FVIII.
Animals
A colony of mice that are homozygous null due to the targeted deletion in exons four and
five of the vWF gene was established using a breeding pairs (JAX Strain B6.129S2-
vWFtm1Wgr/J) from the original colony (Jackson Lab, Bar Harbour, ME). These mice do not
have any circulating levels of vWF and 8–10% of normal FVIII activity, representing severe
von Willebrand disease type 3 with secondary mild HA4,22. A colony of HA mice (C57BL/
6J) with a targeted deletion in exon 16 of the FVIII gene was established from breeding
pairs provided by Dr. Kazazian and Dr. Sarkar from University of Pennsylvania, PA23.
These mice produce no functional FVIII and represent a severe HA mouse model23. Since,
the immune response produced by these mice is qualitatively similar to that observed in
humans, this model is routinely used to investigate the relative immunogenicity of different
FVIII preparations24,25. Mice between 20–25 g and 8–12 weeks old were used for the
immunogenicity studies. All animal handling was performed in accordance with the
guidelines of institutional animal care and use committees (IACUC) at the University at
Buffalo.
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Immunogenicity studies were carried out in HA and vWF−/− mice4,18. Briefly, groups of
mice (n=8) received 4 weekly subcutaneous (s.c.) injections of FVIII or FVIII-aggregates
(10 IU/injection). Each antigen dose consisted of 2 µg of total protein in 100 µL of sterile
Tris buffer. Two weeks after the last injection, plasma samples were collected. Groups of
mice that received saline injections served as a control group. Plasma samples were stored at
−80 °C until analyses.
Measurement of Total Titers
Total antibody titers were determined by a standard antibody capture ELISA as described
earlier4,18,26. Briefly, 96-well plates were coated with rFVIII (2.5 µg/ mL in carbonate
buffer) overnight then blocked with 1% bovine serum albumin (blocking buffer). Samples
were diluted (1:100–1:40000) with blocking buffer. Standard concentrations (12.5–150 ng/
mL) of ESH8 antibody (recognizing 2248–2285 within the C2 domain of the light chain)
were analyzed on each plate to account for plate-to-plate variability. Sample and ESH8
antibody standards were incubated at 37 °C for 1 hr. A 1:1000 dilution of goat antimouse-Ig
(IgG + IgM+ H+L)-alkaline phosphatase conjugate in blocking buffer was added at room
temperature for 1 hr. Detection was made with 100 µL of 1 mg/mL p-nitrophenyl phosphate
solution in diethanolamine buffer (1 M diethanolamine and 0.5 mM MgCl2) for 30 min at
room temperature then quenched with 100 µL 3N NaOH solution. Optical density was
measured at 405 nm using a SpectraMax (Molecular Devices) plate reader. A linear
regression of the plot of absorbance of various dilutions (1:100 to 1:40,000) versus log of
dilution was used to calculate the dilution that gave an optical density equal to the half of the
difference between the maximum and minimum predicted absorbance. The dilution so
obtained was the antibody titer for the sample. To avoid variation between plates a plate
specific parameter was used as described earlier26. Plates were washed between each step
prior to detection and all samples were analyzed in triplicate.
Measurement of Inhibitory Titers
Inhibitory antibody titers were determined using the Nijmegen modification of the Bethesda
assay4,27. Briefly, a calibration curve was constructed using clotting times determined from
various dilutions (1:2 to 1:1,024) of normal coagulation control plasma. Serial dilutions (1:8
to 1:20,000) of mouse plasma samples were prepared in human FVIII-deficient plasma. 100
µl of each diluted plasma sample was mixed with an equal volume of normal human plasma
and incubated at 37°C for 2 hr. Residual FVIII activity was determined at the end of the
incubation using the activated partial thromboplastin time (aPTT) assay and plotted against
the log of dilution. The linear portion of the curve was isolated and linear regression
performed. Inhibitory titers, the dilution at which 50% of FVIII activity remains, were
expressed in Bethesda Units/ml. To minimize the interference from endogenous FVIII on
antibody measurement, plasma samples from vWF−/− mice were heat inactivated (90
minutes at 58°C). This heat treatment neutralizes FVIII but does not affect the heat stable
immunoglobulin28. Heating does not release the inhibitors already complexed to FVIII. Heat
inactivation of plasma samples from HA mice was not necessary as these animals lack
endogenous FVIII. However, selected plasma samples from HA mice were reanalyzed after
heat inactivation to confirm the titer values were unaffected by the procedure.
T cell Proliferation
T cell proliferation was determined by 3H-thymidine incorporation into splenocytes from
immunized animals as described earlier4. Briefly, groups of vWF−/− mice (n=6) received 4
weekly s.c. injections of normal or aggregated FVIII formulations (2 µg/injection). Two
weeks after the last injection animals were sacrificed and spleens were collected and
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homogenized. Splenic T cells were isolated from the uniform suspension with the Dynal
CD4+ negative isolation kit (Invitrogen Inc., Carlsbad, CA). Separately, dendritic cells
(DCs) were isolated from bone marrow of vWF−/− mice (n=4) as described previously29.
DCs were treated with FVIII antigen (2 µg/ml) for 24 hours at 37 °C and 5% CO2. Splenic T
cells (2×105 cells/well) from individual mice were cultured in 96-well plates along with
naïve or FVIII treated murine DCs (7×104 cells/well) in T cell media (RPMI-1640
containing L-glutamine, penicillin/streptomycin, sodium pyruvate, 2-mercaptoethanol, FBS,
polymyxin-B, and 0.22 µm filtered). T cells plated naïve DCs in the absence of antigen
served as the negative control. T cells exposed to Concanavalin A (Con A) served as the
positive control. After 72 hr, 3H-thymidine (1 µCi/well) was added and the cultures were
harvested after 16 hr of incubation using a plate harvester onto a Uni-filter-96® GF/C plate
(Perkin Elmer, Boston, MA). The mean counts from quadruplicate wells were measured
using a TopCount scintillation counter (Perkin Elmer, Boston, MA). To normalize the data
and facilitate comparison between experiments, the activation of T cells was expressed as
the stimulation index (SI). SI is the ratio of 3H-thymidine incorporation in the presence and
absence of FVIII antigen.
Cytokine Analysis
The supernatant media obtained from cells incubated for 72 hr under conditions identical to
those described in the T cell proliferation studies (before 3H-thymidine incorporation) were
used for analysis of cytokine secretion. The cell-containing plates were centrifuged at 300 ×
g for 10 min at 4 °C. The supernatant was collected and stored at −80 °C until analysis.
Supernatants were analyzed for the pro-inflammatory cytokines Interleukin-6 (IL-6) and
Interleukin-17 (IL-17) with ELISA kits (R&D systems, Minneapolis, MN).
Statistical Analysis
Statistical Analysis was conducted using Minitab 16 (Minitab Inc, State College, PA).
Significant differences (p<0.05) were tested using a non parametric two-way Mann-Whitney
test or Kruskal-Wallis ANOVA with Dunn’s post hoc analysis as appropriate.
RESULTS
Preparation and characterization of Aggregates
The aggregation and stability of FVIII is well characterized. Grillo et al. have shown that
thermal stress at 37 °C induces minor tertiary structural changes in FVIII that led to the
formation of soluble aggregates in which the monomeric unit retained substantial native-like
structure16. Conformational analysis using far-UV CD and intrinsic fluorescence suggested
that major conformational changes are not required for the formation of these aggregates.
Further increases in temperature led to the formation of non-native aggregates that were
stabilized by intermolecular beta strands. Native-like and non-native Factor VIII aggregates
were prepared as described by Grillo et al. The conformation of the protein was analyzed
using far-UV CD spectroscopy and intrinsic fluorescence (Figure 1A, 1B)16,18,19. The
formation of aggregates was investigated by SEC (Figure 1C).
The CD spectrum of native FVIII shows a broad negative band at 215 nm suggesting that it
is comprised primarily of β-sheets (Figure 1A). This observation is consistent with the 3D
structure of the protein as elucidated by scattering and molecular modeling studies30. FVIII
was also analyzed following 6 and 24 hr incubations at 37 °C. Thermal stress did not
produce any significant changes in spectral characteristics indicating that there are no
significant alterations in the secondary structure of the protein. Incubation at higher
temperatures resulted in the formation of non-native aggregates. Far-UV CD spectra of the
sample incubated at 80 °C showed a positive band at 205 nm and a small bathochromic shift
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of the broad negative band at 215 nm suggesting the formation of intermolecular beta
strands. This is consistent with previous FTIR spectroscopy that found signatures for
intermolecular beta strands following exposure of FVIII to similar temperatures16.
The samples were also analyzed using fluorescence spectroscopy. The fluorescence
emission maxima of monomeric FVIII were observed at approximately 333 nm, consistent
with previous observations (Figure 1B)19. The fluorescence spectrum of FVIII following 6
hr of incubation at 37 °C did not show any change either in intensity or peak position,
suggesting no significant change in the tertiary structure of the protein. In contrast,
prolonged incubation at 37 °C for 24 hr showed a small reduction in intensity but no change
in λmax. The small drop in intensity may be due to the formation of aggregates and is
consistent with the observation that fractionated protein aggregates showed a decrease in
intensity. The fluorescent intensity of the non-native aggregates generated by incubating at
80 °C showed a substantial loss in intensity that is accompanied by a small red shift. Overall
the data suggest that incubation of FVIII at 37 °C for 24 hr produces native-like aggregates,
but incubation at higher temperatures results in non-native aggregates of FVIII. These
results are consistent with previous reports16–18.
Molecular sieve chromatography and dynamic light scattering studies performed on samples
subjected to similar thermal stress showed about 10% aggregates were formed after 24 hr of
incubation whereas 6 hr of incubation did not induce any detectable aggregate formation16.
SEC analysis was performed to determine the size distribution of aggregates. Native FVIII
showed a broad peak that eluted around 5.5 min (Figure 1C). The observed pattern is
consistent with the heterogeneous molecular weight of the heavy chain, in particular B
domain following intracellular, post-translational processing21. 100% aggregated factor
FVIII elutes in the void volume as a peak around 4.17 min. A small change in convexity at
4.37 min emerges following the 6 hr 37 °C incubation. For native FVIII, this small peak at
4.37 min represented less than 0.5% of the total area. This initial appearance of aggregates
may be due to a slow nucleation process. However, when the incubation period was
extended to 24 hours, this shoulder emerged as a distinct peak consistent with elution of the
completely aggregated species. This peak represented 11% of the total area and was in line
with previous observations. Profiles generated by UV absorption at 215 nm were similar to
the fluorescent data (data not shown). The exclusion limit of the column is 1500kDa. As the
native-like aggregate peak occurs 0.20 min later than the peak observed for the non-native
aggregates, this suggests that the native-like aggregates have a molecular weight lower than
the exclusion limit of the column. Based on a molecular weight of 330 kDa for rFVIII, we
speculate that the native-like aggregates may be comprised of less than five monomers.
These studies suggest that incubation at 37 °C generates aggregates with native-like
conformational states.
Impact of Aggregation on the Immunogenicity of FVIII
The impact of aggregates on FVIII immunogenicity was investigated in HA and vWF−/−
animal models. HA mice are routinely used to evaluate the relative immunogenicity of FVIII
preparations since these mice are not immunologically tolerant of FVIII and produce
immune responses to this molecule that are qualitatively similar to those observed in
humans31,32. Human and murine FVIII also share a high sequence homology (~90%) in
conserved regions of the FVIII molecule33. We previously showed that the administration of
non-native aggregates of FVIII elicited much lower antibody responses in HA mice than
native FVIII18. However, the impact of native-like aggregates has not been studied. To
determine the immunogenic potential of native-like aggregates, antibody responses were
evaluated in the HA mouse model.
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HA mice received 4 weekly injections of either native FVIII, N6 Agg-FVIII, or N24 Agg-
FVIII. Plasma was collected to analyze both the total (Figure 2A) and inhibitory (Figure 2B)
anti-FVIII antibody response. Mice that received N24 Agg-FVIII generated a total anti-
FVIII titer of 21700 ± 2723 (mean ± S.E.; n=8), more than two-fold higher than for mice
that received native FVIII with a total titer of 9566 ± 1467 (mean ± S.E.; n=8). Similar
results were observed for inhibitory antibody titers. Mice that received N24 Agg-FVIII had
more than a two-fold higher mean inhibitory titer of 1503 ± 315 BU/mL (mean ± S.E.; n=9)
than mice that received native FVIII of 608 ± 111 BU/mL (mean ± S.E.; n=6). N6 Agg-
FVIII showed a similar trend for both total and inhibitory titers, but fell short of
significance.
The effect of native-like and non-native aggregates was also studied in vWF−/− mice. vWF
is a carrier protein that is essential for the plasma survival of FVIII. In the absence of vWF,
the endogenous concentration of FVIII drops to 8–10% of normal34,35. Thus, vWF −/− mice
show hemophilia-like characteristics in that they reflect FVIII deficiency22,24. Similar to that
observed in HA mice, native-like aggregate treatment (N24 Agg-FVIII) showed
significantly higher (p<0.05) mean total antibody titers 19425 ± 3443 (S.E.; n=8) compared
to animals that received free FVIII 8192 ± 853 (S.E.; n=8) (Figure 3A). Similar observations
were made for neutralizing titers as well (Figure 3B). In these mice the inhibitory titers
elicited by both N6 Agg-FVIII 452 ± 57 BU/mL (mean ± S.E.; n=8) and N24 Agg-FVIII
523 ± 61 BU/mL (mean ± S.E.; n=8) were significantly increased compared to native FVIII
236 ± 28 BU/mL (mean ± S.E.; n=8). For the groups of mice which received 5% Agg-FVIII
and 20% Agg-FVIII, the mean inhibitory were comparable to each other and lower than the
native FVIII group, consistent with our previous findings in HA mice18. No inhibitory titers
were observed following saline treatment for either HA or vWF−/− mice. These results
suggest that the presence of native-like aggregates in FVIII protein formulations is more
immunogenic than non-native aggregates.
An interesting observation is that in both animal models, N6 Agg-FVIII was more
immunogenic than native FVIII even though CD and fluorescence studies showed no
conformational changes from native state and molecular sieve chromatography and dynamic
light scattering detected minimal aggregate development. The magnitude of immune
response did not correlate with amount of aggregates detected by SEC.
Impact of Aggregates on T-Cell Proliferation
While it was clear that the native-like aggregates of FVIII provoked a greater B cell
response than native FVIII as determined by inhibitory titers, it was of interest to determine
if mechanistically this included a greater T cell based response as well. To address this
question, the generation and proliferation of CD4+ T cells were studied using a 3H-
thymidine T cell proliferation assay. T cells derived from vWF−/− mice immunized with
either native FVIII or FVIII aggregates were assayed in vitro for their response to native
FVIII. Following restimulation with native FVIII, the T cells derived from mice immunized
with the native-like aggregates showed a significantly increased stimulation index compared
to T cells of mice immunized with native FVIII (Figure 4). For splenic T cells harvested
from mice immunized with N6 Agg-FVIII, the mean SI of 32.8 ± 4.9 (S.E.; n=6) was
significantly higher (p>0.05, Mann–Whitney nonparametric test) than for mice immunized
with native FVIII 11.5 ± 3.7 (S.E.; n=6). Similarly, for the group that received N24 Agg-
FVIII, the mean SI of 44.0 ± 4.3 (S.E.; n=6) was ~4 fold higher compared to the native
FVIII group. The mean SI for both non-native aggregate treatments groups was lower than
native FVIII with 5.6 ± 0.9 (S.E.; n=6) for 5% Agg-FVIII and 4.8 ± 0.7 (S.E.; n=6) for 20%
Agg-FVIII. We conclude that immunization of mice with the native-like FVIII aggregates
induces a greater T cell response to in vitro re-stimulation than either the native FVIII or the
non-native aggregated FVIII in vWF−/− mice.
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Impact of Aggregates on Pro-inflammatory Cytokine Secretion
The activation of T cells requires a co-stimulatory signal provided by cytokine secretion36. T
cells release pro-inflammatory cytokines such as IL-6 and IL-17 that trigger an immune
response37. To investigate whether native-like aggregates induce production of pro-
inflammatory cytokines, the secretion of IL-6 and IL-17 induced by CD4+ T cells obtained
from spleens of animals that received native or aggregated FVIII was determined using by
ELISA. The concentration of pro-inflammatory cytokines was much higher in the groups
treated with native-like aggregates when compared to the groups treated with native FVIII or
non-native aggregates. The trends observed for both inhibitory titers and T cell proliferation
continued for cytokine secretion (Table 1). N24 Agg-FVIII significantly increased IL-6
secretion, but N6 Agg-FVIII did not produce a significant increase, likely due to the limited
sample size (n=3). IL-17 production was significantly increased by both N6 Agg-FVIII and
N24 Agg-FVIII as well as significantly decreased by both 5% Agg-FVIII and 20% Agg-
FVIII. These cytokines are key elements in modulating immune responses and their elevated
levels suggest that native-like aggregates are more immunogenic than non-native aggregates
or native FVIII.
DISCUSSION
Immunogenic responses against therapeutic proteins are not only an important safety issue,
but can also influence efficacy. Antibodies may bind to proteins altering pharamacokinetics
or interact with critical epitopes directly neutralizing activity38,39. The causes of
immunogenicity can be classified as product, treatment and patient related issues40,41.
Product-related factors include protein sequence, presence of immunodominant epitopes,
aggregation, the effects of glycosylation on protein degradation, exposure of antigenic sites
and solubility of the protein13,40,42–45. In particular, the presence of native-like aggregates
has been shown to be highly immunogenic14. Our previous work has shown that non-native
aggregates of FVIII generated by heat denaturation were less immunogenic than the native
monomer18. FVIII is also prone to form native-like aggregates and we hypothesized that
these highly immunogenic species would lead to an inhibitory immune response16. A high
incidence of inhibitor development has been observed in patients that received a plasma
derived FVIII pasteurized at 63 °C for 10 hours46. It is possible that the increases in
immunogenicity resulted from the generation of subvisible particles or native-like aggregate
species that could not be distinguished from the native protein by the analytical techniques
employed in those experiments. We generated native-like aggregates and administered the
formulations to HA mice that produce no active, endogenous FVIII and lack innate
tolerance, as well as vWF−/− mice that have reduced FVIII concentrations but an innate
tolerance to the protein.
The results showed that native-like aggregates elicited a higher neutralizing antibody
response in both of these animal models (Figure 2, Figure 3). Similar conclusions have been
drawn from previous studies of other therapeutic proteins. Native-like aggregates of both of
erythropoietin alpha and recombinant human interferon alpha are highly immunogenic15,47.
Native-like aggregates retain more of the conformational epitopes recognized by the
immune system than non-native aggregates. In addition to the retention of higher order
structure, native-like aggregates often present antigens in a repetitive manner that enhances
immune responses. Even subtle changes such as those observed with N6 Agg-FVIII, which
produced no conformational changes detected by biophysical techniques and displayed only
a slight trend towards an aggregated species by SEC, were capable of inducing an enhanced
immune response. It is possible that several factors could contribute to this observation,
including the presence of sub-visible particles. The size of the aggregates may also be a
critical factor in eliciting immunogenicity and longer incubation periods could also lead to
the formation of larger aggregate complexes. The current study design does not address the
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role of aggregate size on immunogenicity, but it is nonetheless an important issue. However,
the results demonstrate that native-like aggregates are more immunogenic than monomeric
native FVIII or non-native aggregates of FVIII.
The mechanism of immune responses against protein aggregates has been the subject of
several investigations. It is known that B cells process repetitive antigens in aggregates by
cross linking B cell receptors and intracellular signaling pathways involving Bruton’s
tyrosine kinase/Tec Kinase48. This is sufficient to initiate the proliferation of B cells to
produce antibodies independent of T cells, but antigen processing and presentation could
also involve T cell help40 and this aspect of T-cell help for aggregate mediated
immunogenicity has received very little attention49. Since the immune response against
FVIII is a T cell based response, we investigated the role of T cells in the immunogenicity of
native-like aggregates. Mice were immunized with different formulations to generate CD4+
T cell clones. These splenic CD4+ T cells were isolated and re-stimulated with native FVIII.
Clinically this study design is akin to a patient who develops inhibitory titers and effector T
cell clones upon exposure to native-like aggregates present in a therapeutic preparation, and
the subsequent reactivation of those clones with further dosing. T cell clones isolated from
mice that received native-like aggregates were activated at significantly higher levels
compared to clones from mice receiving monomeric, native FVIII. This could be due to
several contributing factors including: (i) native-like aggregates of FVIII generate a greater
CD4+ memory T cell response than the other forms of FVIII, (ii) high avidity/affinity T cell
clones are generated following the administration of native-like aggregates that proliferate in
an efficient manner in response to FVIII epitopes50, and/or (iii) native-like aggregates
present neo or cryptic epitopes to antigen presenting cells (such as dendritic and B cells) that
can then react with monomeric FVIII25,51.
FVIII is efficiently taken-up and processed by antigen presenting cells. The glycosylation
pattern in FVIII has been shown to promote uptake by antigen presenting cells via C-type
lectins and result in efficient presentation to T cells for activation21. The presence of native-
like aggregates can promote further uptake using Toll-like receptors. Cross talk between C-
type lectin receptors and TLR could also provide higher immune responses52. These cellular
interactions are supported by the enhanced secretion of the pro-inflammatory cytokines IL-6
and IL-17 (Table 1).
Based on conformational studies, it was demonstrated that minor conformational changes
initiating aggregation involve the lipid binding domain20. Amino acid residues 2191–2210,
2241–2290, 2291–2330 all constitute CD4+ T cell epitopes present in this same aggregation
prone region53,54. More detailed studies are warranted to investigate whether the minor
conformational changes associated with the aggregation process expose neo or cryptic
epitopes that lead to generation of efficient T cell clones against native FVIII, or enhance the
presentation of recognized epitopes.
Overall, native-like FVIII aggregates produced a greater immune response than both native
FVIII and non-native FVIII aggregates. This increase in antibody titers may be due to both
B cell and T cell responses and is accompanied by elevated secretion of the pro-
inflammatory cytokines IL-6 and IL-17. Our results suggest that it is not just the presence or
absence of aggregates, but whether those species are native-like or non-native that can play a
critical role in eliciting immunogenic responses.
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A: The representative far UV-CD spectrum of rFVIII and aggregated rFVIII (80µg/100µL)
in Tris buffer (300 mM NaCl, 25 mM Tris and 5 mM CaCl2, pH 7.0). The CD spectra were
acquired multiple times with multiple samples and representative spectra are shown.
B: The representative fluorescence emission spectra of fractionated native and aggregate
(80µg/mL) species in Tris buffer (25 mM Tris, 300 mM NaCl, 5 mM CaCl2, pH 7.0). The
samples were excited at 280 nm. The fluorescence spectra were acquired multiple times with
multiple samples and representative spectra are shown.
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C: Size exclusion studies of native, native-like aggregates, and non-native aggregates of
FVIII. Fluorescent intensity was monitored at 285ex/335em following separation on a
Biosep-SEC-4000-S column run with a 0.5 mL/min Tris buffer elution.
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The mean of inhibitory titers (cross) and individual (closed circles) antibody titers against
FVIII in HA mice immunized via s.c. administration of native and native-like aggregates of
FVIII. (A) Total anti-FVIII titers as determined by ELISA. (B) Inhibitory anti-FVIII titers as
determined by the Nijmegen modification of the Bethesda assay. Significant differences are
shown as determined by Kruskal-Wallis ANOVA with Dunn’s post hoc.
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The mean of inhibitory titers (cross) and individual (closed circles) antibody titers against
FVIII in vWF−/− mice immunized via s.c. administration of native, native-like aggregates,
and non-native aggregates of FVIII. (A) Total anti-FVIII titers as determined by ELISA. (B)
Inhibitory anti-FVIII titers as determined by the Nijmegen modification of the Bethesda
assay. Significant differences are shown as determined by Kruskal-Wallis ANOVA with
Dunn’s post hoc.
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The stimulation indices of different splenocytes from mice immunized with different
preparations of FVIII. The mean stimulation index (cross) and individual (filled circles)
stimulation indices from individual spleens (n=6) of different treatment groups as
determined by 3H-thymidine incorporation T cell proliferation assay in vWF−/− mice.
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